Lebrikizumab

Eli Lilly's Kisunla (donanemab-azbt) receives approval from Japan's MHLW for early symptomatic Alzheimer’s treatment. The approval is based on the Phase III TRAILBLAZER-ALZ 2 study, showing Kisunla's efficacy in reducing clinical decline and amyloid plaques. However, it carries risks like amyloid-related imaging abnormalities and infusion-related reactions.

FDA approved Eli Lilly's EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor, for treating moderate-to-severe atopic dermatitis in adults and children 12+ years old who weigh at least 88 pounds and whose condition is not well controlled with topical prescription therapies. Results from studies ADvocate 1, 2, and ADhere showed 38% of treated patients achieved clear or almost-clear skin at 16 weeks, compared to 12% with placebo. EBGLYSS also provided itch relief, with 43% experiencing relief at 16 weeks, compared to 12% on placebo. The treatment was also approved in Europe and Japan, with additional market approvals expected.

FDA approves Eli Lilly's EBGLYSS, a new drug targeting IL-13 cytokine to treat moderate-to-severe atopic dermatitis in adults and children 12+ years. Clinical trials showed 38% of participants had clear or nearly clear skin at 16 weeks, with 77% maintaining results at 1 year. Common side effects include eye inflammation and injection site reactions.

FDA approves Eli Lilly's Ebglyss, an injection for moderate-to-severe eczema in patients 12+ weighing at least 88 lbs. Studies show 38% achieved clear or almost-clear skin at 16 weeks, and 43% felt itch relief. Ebglyss offers a new biologic option for those unresponsive to topical treatments.

FDA approves Eli Lilly’s Ebglyss for eczema, Novartis’ Kisqali for early breast cancer, Merck’s Keytruda for malignant pleural mesothelioma, J&J’s Rybrevant for advanced lung cancer, and AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis.

MaxCyte partners with Kamau Therapeutics, Arvato Systems with Advanco, Revance Therapeutics' acquisition impacted by Crown Laboratories, Lifebit and CanPath strategic partnership, Kajeet and Avery Telehealth partnership. FDA approves Apple's sleep apnea detection, Roche's Ocrevus injectable, Novartis Kisqali, Lilly's EBGLYSS, issues alert on Astellas' Veozah, clears Eversense CGM system. Nura Bio raises $68 million, Arzeda $38 million. Cigna's Express Scripts sues FTC, Burson launches Decipher Health, short interest in healthcare stocks rises, Hill Holliday's Quest, Ascendis Pharma's positive Phase 3 results, WHO approves Bavarian Nordic's mpox vaccine, J&J's talc verdict overturned, Prime Therapeutics' new vision, Blue Matter acquires Sam Brown Inc.

FDA approves Eli Lilly's Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis in adults and children aged 12+, based on ADvocate 1, 2, and ADhere studies showing 38% achieved clear or almost-clear skin at 16 weeks versus 12% with placebo, with 77% maintaining results at one year.

The FDA approved Ebglyss (lebrikizumab-lbkz), a biologic treatment for moderate-to-severe atopic dermatitis in adults and children 12 years and older. Ebglyss, a once-a-month injectable IL-13 inhibitor, showed significant skin clearance and itch relief in phase 3 trials, with 38% achieving clear or almost-clear skin at 16 weeks. Notably, it proved effective in people of color, addressing a gap in dermatologic treatment data. The drug's cost is $3,500 per pen, with potential copay assistance.

FDA approves Ebglyss™ (lebrikizumab-lbkz) for moderate to severe atopic dermatitis in patients 12+ years old not controlled by topical therapies. Supported by 3 clinical trials (ADvocate1, ADvocate2, ADhere), Ebglyss showed significant improvement in IGA scores, EASI-75, EASI-90, and pruritus NRS. Common adverse reactions include conjunctivitis, injection site reactions, and herpes zoster. Available in 250mg/2mL prefilled pens/syringes, to be administered subcutaneously.

The FDA approved Lilly’s Ebglyss (lebrikizumab-lbkz) for moderate to severe atopic dermatitis in adults and children aged 12+. Based on ADvocate 1, 2, and ADhere studies, 38% achieved clear skin within 16 weeks, and 77% maintained it for a year. Recommended starting dose is 500 mg, followed by monthly maintenance. Conjunctivitis was the most reported side effect.